Vaxess - About the company
Vaxess is a series D company based in Cambridge (United States), founded in 2011 by Michael Schrader and Kathryn Kosuda. It operates as a Developer of novel vaccine formulations using silk stabilization platform. Vaxess has raised $117M in funding from investors like RA Capital Management, Norwich Ventures and Engine. The company has 3262 active competitors, including 1121 funded and 773 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio.
Company Details
Developer of novel vaccine formulations using a silk stabilization platform. Technology includes extracting fibroin from silk in which biological compounds are encapsulated to provide heat stability. It is also developing product formats that enable novel routes of administration like microneedles for transdermal applications. It has developed MIMIX therapies that help in treating cancers such as skin cancers, breast cancer, and infectious diseases.
- Website
- vaxess.com/
- Social
Key Metrics
Founded Year
2011
Location
Cambridge, United States
Stage
Series D
Total Funding
$117M in 30 rounds
Latest Funding Round
Investors
Ranked
69th among 3262 active competitors
Employee Count
72 as on Mar 31, 2026
Similar Companies
Sign up to download Vaxess' company profile
Vaxess's funding and investors
Vaxess has raised a total funding of $117M over 30 rounds. Its first funding round was on Apr 25, 2012. Vaxess has 18 institutional investors.
Here is the list of recent funding rounds of Vaxess:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 27, 2025 | 4806663 | Series D | 7877732 | 7459505 | 7789490 | 5232629 |
Feb 14, 2025 | 8623792 | Series D | 8050115 | 7555987 | 1060425 | |
Sep 16, 2024 | 3662195 | Grant (prize money) | 2928248 | 8714556 | 3968725 |
Access funding benchmarks and valuations. Sign up today!View details of Vaxess's funding rounds and investors
Vaxess' founders and board of directors
Founder? Claim ProfileThe founders of Vaxess are Michael Schrader and Kathryn Kosuda.
Here are the details of Vaxess' key team members:
- Michael Schrader: Co-Founder and CEO of Vaxess and founder of 1 other company.
- Kathryn Kosuda: Co-Founder of Vaxess and founder of 1 other company. Contact Info: 1 email address
View details of Vaxess's Founder profiles and Board Members
Vaxess' employee count trend
Vaxess has 72 employees as of Mar 26. Here is Vaxess's employee count trend over the years:
Uncover Vaxess' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Vaxess's Competitors and alternates
Top competitors of Vaxess include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Vaxess, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 75/100 | |
3rd | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
5th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
6th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
7th | Karyopharm 2008, Newton (United States), Public | Biopharmaceutical company focused on developing and commercializing innovative cancer therapies | $98.4M | 71/100 | |
8th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
9th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
10th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
69th |  Vaxess 2011, Cambridge (United States), Series D | Developer of novel vaccine formulations using silk stabilization platform | $117M | 65/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Vaxess's competitors? Click here to see the top ones
Vaxess's Investments and acquisitions
Vaxess has made no investments or acquisitions yet.
Reports related to Vaxess
Here is the latest report on Vaxess's geography:
News related to Vaxess
Filter this listMedia has covered Vaxess for a total of 2 events in the last 1 year, 1 of them has been about company updates.
•
Terrestrial Bio Leases 42,000 SF for HQ at King Street’s Allston Labworks in BostonCRE Market Beat•Mar 26, 2026•Vaxess
•
Microneedle vaccine patch company Terrestrial Bio raises $50M for GLP-1 deliveryEndpoints•Mar 25, 2026•Vaxess, Engine Ventures, Global Health Investment, SiteGround and 1 other
•
Vaxess Inks $9M Funding RoundMassinvestor•Apr 25, 2025•Vaxess, RA Capital Management, Engine Ventures
•
•
•
•
Vaccine patch maker Vaxess raises $12M, names new CEODrug Delivery Business•May 22, 2024•Vaxess, RA Capital Management, Engine Ventures, Mission BioCapital and 5 others
•
Vaxess Technologies Raises $9M in FundingFinSMEs•Sep 13, 2023•Vaxess, RA Capital Management, Engine, Global Health Investment and 1 other
•
AstraZeneca and Vaxess developing skin patch mRNA vaccines for pandemic fluEndPoints News•Aug 24, 2023•AstraZeneca, Vaxess
•
Vaccine patch maker Vaxess names former Sanofi exec as chief strategy officerDrug Delivery Business•Mar 22, 2023•Vaxess, Sanofi
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Vaxess
Explore our recently published companies
- Autocal - Thane based, 2002 founded, Funding Raised company
- Indo Amines - Thane based, 1994 founded, Public company
- Taro International - Haifa based, 1992 founded, Unfunded company
- SmartCart AI - San Francisco based, Unfunded company
- 365 Retail Markets - London based, 2008 founded, Unfunded company
- Bishop Paiute Development Corporation - Bishop based, 2009 founded, Funding Raised company
